Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
Slow to react, backtracking and changing their approach, poor performance in core products like NIPT. Even though revenue has increased with the help of covid testing the actual underlying profit has not materialised. Too many BOD and employees on the payroll! Oh and and don't get me started with LRs other company commitments.
A molecular diagnostics company performing so poorly in the past 18/12 when the sector is booming with testing requirements, is nothing short of poor leadership.
When was the last time we heard of confirmed contracts apart from covid contracts which don't have a minimum spend? NIPT? DPYD? Supposed US contracts? Not enough substance for this sp to actually move.
This is why Pi's and institutional investors have lost faith and why the sp is dwindling at these low levels.
I'm not surprised pi's are getting fed up. The sp has been abysmal over the past 15 months, just like the management's performance.
But saying that you know all will end well here, there's too much going on. Even though it's at snail pace, slowly but surely!
Mandatory day 2 pcr tests for all travellers returning from abroad. This should further boost income for Yourgene. Hopefully a nice RNS on Monday confirming the detection by clarigene of this new variant should add more interest and get the sp moving back up.
https://twitter.com/Yourgene_Health/status/1377178878716702723?s=19
Great news!
Cytox tests to launch in the US q2 2021 too.
https://twitter.com/CytoxDx/status/1369924403899797504?s=19
https://bidstats.uk/tenders/2021/W09/745931131
Would be a nice contract for either YGEN or MHC. Either way win win for YGEN. Would make sense for a Manchester based supplier to provide Covid testing for MAG.
In a notable milestone, Yourgene has signed up its first US customer for the Coastal Genomics technology. Whilst “only” worth a minimum of $1.5m over five years, the agreement is important for a number of reasons: i) it validates the commercial potential of the Coastal technology; ii) it adds to Yourgene’s growing presence in the important US market; and iii) it is with a large clinical laboratory group, initially in reproductive health, but with scope to be expanded into other applications in due course. We therefore believe it could be worth significantly more than the quoted minimum value over time. This was anticipated, hence we make no change to our forecasts at this stage, but view this agreement as validating the rationale for acquiring Coastal Genomics in August. We expect this to be the first of a number of partners for the technology, opening up another growth avenue for the group.
Lionheart,
Additional shares are not a reflection on this specific deal but a reflection on the acquisition of coastal genomics. This share giveaway was part of that deal. Yourgene is looking at the bigger picture here, this new contract was a mere trigger in achieving the milestone for the shares to be given.
Imo it's better to have constructed a deal this way rather than issuing the shares prior to any new contracts being won and solely when coastal genomics was acquired.
Positive signs indeed. An entry into the US market is how this RNS should be looked at. The potential of the US market is huge and we should all look forward to Yourgene gaining exposure/market share in the near future. This is just the start of many more deals to come which will be much more significant in value.
Masterblaster,
The sentiment is still good. Don't fall for certain crafty posters. There are many wolves hidden in sheep clothing on this BB, who have their own specific agenda.
It's been a healthy pullback. Onwards and upwards from here.
Best of Luck to all (apart from the certain few)
Brilliant news today! Tie up with LBA will be a good earner over then next year at least. Bottom line from previous TU is around £50 for YGEN for each test. It would definitely not be £25.
In terms of testing I would not expect to see 4m passengers in the coming year. Even if it's a fraction of this let's say 10% in the coming year. Each person currently requires 3 covid tests for each trip (Obviously this may change over time). If you do the maths then this is a significant amount of revenue over the coming year.
We are awaiting PMs lockdown easing plans today. The market should overtime realise the opportunity here.
IMO revenues over the next year will be significantly higher than current forecasts.
Cooper you are absolutely correct. The reward time for shareholders is approaching us.
Rocket time!
GLA
I really hope new investor expectations are not through the roof. This is a medium to long term investment and one should not expect this to moonshot overnight like NCYT did. Obviously unless any material news is worthy of a moonshot. There will be a steady rise upwards imo.
DYOR, this company has a fantastic portfolio of products. Life saving world class products. YoY growth and revenues are expected to increase further. I truly believe once the lockdown and the effect of covid is reduced we will once again hear of many new contracts. This company is like a coiled spring affected during covid but ready to spring into action as soon as circumstances allow it to.
This is most certainly not a 'pump and dump' share!
My recommendations to new investors is to research away and hopefully you will also see the potential in this company as I do.
Good luck to all LTH and to new investors.
Ash
Moneymunch,
Capacity has increased to 20,000 for in house testing since December. Although capacity to produce the tests are significantly higher.
I don't expect YGEN to land UK government contracts. Covid contracts will most likely be abroad. If you listen to LRs most recent TU he briefly mentioned upcoming covid tie ups to be finalised soon. Dan has hinted this may land sooner than expected.
NIPT and DPYD products are future money makers imo. These products will provide a significant increase in revenue stream over the coming years. We just need to get back to some sort of normality and then news flow will progressively increase.